6月17日，据CDE官网消息，默沙东研发（中国）有限公司联合申请药品“注射用MK-2870”，获得临床试验默示许可，受理号CXSL2400214。
公示信息显示，药品“注射用MK-2870”适应症：非小细胞肺癌。
默沙东研发（中国）有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.